<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:54:13Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6250246" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6250246</identifier>
        <datestamp>2018-12-10</datestamp>
        <setSpec>lwwopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Crit Care Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Crit. Care Med</journal-id>
              <journal-id journal-id-type="publisher-id">CCM</journal-id>
              <journal-title-group>
                <journal-title>Critical Care Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0090-3493</issn>
              <issn pub-type="epub">1530-0293</issn>
              <publisher>
                <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6250246</article-id>
              <article-id pub-id-type="pmcid">PMC6250246</article-id>
              <article-id pub-id-type="pmc-uid">6250246</article-id>
              <article-id pub-id-type="pmid">30222631</article-id>
              <article-id pub-id-type="art-access-id">00037</article-id>
              <article-id pub-id-type="doi">10.1097/CCM.0000000000003405</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Online Clinical Investigations</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Vitamin D to Prevent Lung Injury Following Esophagectomy—A Randomized, Placebo-Controlled Trial*</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Parekh</surname>
                    <given-names>Dhruv</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff1">1–</xref>
                  <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dancer</surname>
                    <given-names>Rachel C. A.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Scott</surname>
                    <given-names>Aaron</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>D’Souza</surname>
                    <given-names>Vijay K.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Howells</surname>
                    <given-names>Phillip A.</given-names>
                  </name>
                  <degrees>FRCA</degrees>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mahida</surname>
                    <given-names>Rahul Y.</given-names>
                  </name>
                  <degrees>MRCP</degrees>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tang</surname>
                    <given-names>Jonathan C. Y.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cooper</surname>
                    <given-names>Mark S.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fraser</surname>
                    <given-names>William D.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tan</surname>
                    <given-names>LamChin</given-names>
                  </name>
                  <degrees>FRCS</degrees>
                  <xref ref-type="aff" rid="aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gao</surname>
                    <given-names>Fang</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Martineau</surname>
                    <given-names>Adrian R.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tucker</surname>
                    <given-names>Olga</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Perkins</surname>
                    <given-names>Gavin D.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff3">3</xref>
                  <xref ref-type="aff" rid="aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Thickett</surname>
                    <given-names>David R.</given-names>
                  </name>
                  <degrees>DM</degrees>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <aff id="aff1"><label>1</label>Birmingham Acute Care Research Group, Institute of Inflammation and Aging, University of Birmingham, Birmingham, United Kingdom.</aff>
                <aff id="aff2"><label>2</label>Queen Elizabeth Hospital University Hospitals, Birmingham NHS Foundation Trust, Birmingham, United Kingdom.</aff>
                <aff id="aff3"><label>3</label>Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, United Kingdom.</aff>
                <aff id="aff4"><label>4</label>Academic Department of Anaesthesia, Critical Care, Resuscitation and Pain, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.</aff>
                <aff id="aff5"><label>5</label>Norwich Medical School, University of East Anglia, Norwich, United Kingdom.</aff>
                <aff id="aff6"><label>6</label>Discipline of Medicine, Concord Clinical School, University of Sydney, NSW, Australia.</aff>
                <aff id="aff7"><label>7</label>University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom.</aff>
                <aff id="aff8"><label>8</label>Blizard Institute, Queen Mary University of London, London, United Kingdom.</aff>
              </contrib-group>
              <author-notes>
                <corresp id="c1">For information regarding this article, E-mail: <email xlink:href="d.parekh@bham.ac.uk">d.parekh@bham.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>12</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>16</day>
                <month>11</month>
                <year>2018</year>
              </pub-date>
              <volume>46</volume>
              <issue>12</issue>
              <fpage>e1128</fpage>
              <lpage>e1135</lpage>
              <permissions>
                <copyright-statement>Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and Wolters Kluwer Health, Inc.</copyright-statement>
                <copyright-year>2018</copyright-year>
                <license license-type="open-access">
                  <license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri xlink:type="simple" xlink:href="ccm-46-e1128.pdf"/>
              <abstract abstract-type="toc">
                <p>Supplemental Digital Content is available in the text.</p>
              </abstract>
              <abstract>
                <sec>
                  <title>Objectives:</title>
                  <p>Observational studies suggest an association between vitamin D deficiency and adverse outcomes of critical illness and identify it as a potential risk factor for the development of lung injury. To determine whether preoperative administration of oral high-dose cholecalciferol ameliorates early acute lung injury postoperatively in adults undergoing elective esophagectomy.</p>
                </sec>
                <sec>
                  <title>Design:</title>
                  <p>A double-blind, randomized, placebo-controlled trial.</p>
                </sec>
                <sec>
                  <title>Setting:</title>
                  <p>Three large U.K. university hospitals.</p>
                </sec>
                <sec>
                  <title>Patients:</title>
                  <p>Seventy-nine adult patients undergoing elective esophagectomy were randomized.</p>
                </sec>
                <sec>
                  <title>Interventions:</title>
                  <p>A single oral preoperative (3–14 d) dose of 7.5 mg (300,000 IU; 15 mL) cholecalciferol or matched placebo.</p>
                </sec>
                <sec>
                  <title>Measurements and Main Results:</title>
                  <p>Primary outcome was change in extravascular lung water index at the end of esophagectomy. Secondary outcomes included Pa<sc>o</sc><sub>2</sub>:F<sc>io</sc><sub>2</sub> ratio, development of lung injury, ventilator and organ-failure free days, 28 and 90 day survival, safety of cholecalciferol supplementation, plasma vitamin D status (25(OH)D, 1,25(OH)<sub>2</sub>D, and vitamin D-binding protein), pulmonary vascular permeability index, and extravascular lung water index day 1 postoperatively. An exploratory study measured biomarkers of alveolar-capillary inflammation and injury. Forty patients were randomized to cholecalciferol and 39 to placebo. There was no significant change in extravascular lung water index at the end of the operation between treatment groups (placebo median 1.0 [interquartile range, 0.4–1.8] vs cholecalciferol median 0.4 mL/kg [interquartile range, 0.4–1.2 mL/kg]; <italic>p</italic> = 0.059). Median pulmonary vascular permeability index values were significantly lower in the cholecalciferol treatment group (placebo 0.4 [interquartile range, 0–0.7] vs cholecalciferol 0.1 [interquartile range, –0.15 to –0.35]; <italic>p</italic> = 0.027). Cholecalciferol treatment effectively increased 25(OH)D concentrations, but surgery resulted in a decrease in 25(OH)D concentrations at day 3 in both arms. There was no difference in clinical outcomes.</p>
                </sec>
                <sec>
                  <title>Conclusions:</title>
                  <p>High-dose preoperative treatment with oral cholecalciferol was effective at increasing 25(OH)D concentrations and reduced changes in postoperative pulmonary vascular permeability index, but not extravascular lung water index.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>acute respiratory distress syndrome</kwd>
                <kwd>cholecalciferol</kwd>
                <kwd>esophagectomy</kwd>
                <kwd>vitamin D</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>STATUS</meta-name>
                  <meta-value>ONLINE-ONLY</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>SDC</meta-name>
                  <meta-value>T</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <p>Prevention of the acute respiratory distress syndrome (ARDS) has become a focus of research in recent years, with the development of prediction scores (<xref rid="R1" ref-type="bibr">1</xref>), prevention trials (<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R3" ref-type="bibr">3</xref>) and a growing evidence of other potential biological therapies to prevent ARDS (<xref rid="R4" ref-type="bibr">4</xref>).</p>
            <p>ARDS is common after esophagectomy with studies reporting a frequency between 13% and 30% (<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R5" ref-type="bibr">5</xref>–<xref rid="R7" ref-type="bibr">7</xref>). During open surgery, access to the esophagus is attained by deflation of one lung and maintenance of one-lung ventilation (OLV) exposing the ventilated lung to volutrauma, hyperoxia, and barotrauma (<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>). Concurrently the deflated lung is exposed to ischemia-reperfusion injury (<xref rid="R10" ref-type="bibr">10</xref>). The pathophysiologic changes of lung injury post esophagectomy are similar but less exaggerated than in ARDS patients (<xref rid="R11" ref-type="bibr">11</xref>–<xref rid="R13" ref-type="bibr">13</xref>). This high-risk population has been validated for assessing potential therapies to assess biological efficacy and prevent ARDS (<xref rid="R2" ref-type="bibr">2</xref>).</p>
            <p>Vitamin D (VD) deficiency is common (<xref rid="R14" ref-type="bibr">14</xref>). VD has important functions besides bone, and calcium homeostasis and its immunomodulatory actions may play a role in the pathogenesis of ARDS (<xref rid="R15" ref-type="bibr">15</xref>). Studies report a high prevalence of VD deficiency (VDD) in the critically ill (<xref rid="R16" ref-type="bibr">16</xref>) with an association with increased rates of infection (<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>) acute respiratory failure (<xref rid="R19" ref-type="bibr">19</xref>), acute kidney failure (<xref rid="R20" ref-type="bibr">20</xref>), sepsis (<xref rid="R18" ref-type="bibr">18</xref>, <xref rid="R21" ref-type="bibr">21</xref>), and mortality in some (<xref rid="R22" ref-type="bibr">22</xref>), but not all studies (<xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R24" ref-type="bibr">24</xref>).</p>
            <p>We have previously reported severe VDD in a cohort of ARDS patients (<xref rid="R25" ref-type="bibr">25</xref>). VDD (plasma 25(OH)D &lt; 50 nmol/L) was ubiquitous in ARDS patients and present in the vast majority of patients at risk of developing ARDS following esophagectomy. Experimental studies suggest a protective effect of VD in the lung. In a murine model of intratracheal lipopolysaccharide challenge, dietary-induced VDD resulted in exaggerated alveolar inflammation, epithelial damage, and hypoxia which were abrogated by cholecalciferol treatment (<xref rid="R21" ref-type="bibr">21</xref>). In vitro, 25(OH)D has trophic effects on primary human alveolar type II cells affecting over 600 genes (<xref rid="R25" ref-type="bibr">25</xref>). We conducted a phase 2 randomized, placebo-controlled trial to test our hypothesis that high-dose cholecalciferol treatment preoperatively reduces markers of alveolar epithelial lung injury seen post esophagectomy, a high-risk population of developing ARDS. Results of these studies have been previously reported in the form of an abstract (<xref rid="R26" ref-type="bibr">26</xref>).</p>
            <sec sec-type="methods">
              <title>MATERIALS AND METHODS</title>
              <sec>
                <title>Study Design</title>
                <p>A randomized, double-blind placebo-controlled trial, recruited patients from October 3, 2012, to January 26, 2015, at three hospitals in the United Kingdom. Ethics approval was obtained from South Birmingham Research Ethics Committee (REC 12/WM/0092). Trial registration identification ISRCTN27673620 and EudraCT 2012-000332-25. The study protocol has been previously published (<xref rid="R27" ref-type="bibr">27</xref>). Detailed methods can be found in the <bold>online supplemental material</bold> (Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>).</p>
              </sec>
              <sec>
                <title>Eligibility Criteria</title>
                <p>Patients undergoing a planned thoracic esophagectomy and 18 years old or older if male, aged 55 or more than 2 years since menopause if female and were able to give written informed consent. Exclusion criteria detailed in the online supplemental material (Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>).</p>
              </sec>
              <sec>
                <title>Drug Randomization and Masking</title>
                <p>The trial drug manufacturer, Novalabs (Leicester, United Kingdom), produced computer-generated randomization sequence using a block size of 10 with equal allocation between active and placebo groups. Pharmacy, research staff, clinical teams, and patients were masked to randomization and treatment allocation.</p>
              </sec>
              <sec>
                <title>Drug Administration</title>
                <p>Participants received either a single dose of drug (oral cholecalciferol oily solution Vigantol (Novalabs), 300,000 IU [7.5 mg; 15 mL]) or matched placebo (Miglyol 812 oil, the vehicle for cholecalciferol in Vigantol) 3–14 days prior to planned esophagectomy.</p>
              </sec>
              <sec>
                <title>Primary Outcome</title>
                <p>Primary outcome was change in extravascular lung water index (EVLWI) measured by Pulse Contour Continuous Cardiac Output (PiCCO<sub>2</sub>) thermodilution catheter (Pulsion Medical Systems, Feldkirchen, Germany) at the end of the esophagectomy (measured within 1 hr postoperatively). PiCCO<sub>2</sub> EVLWI has been shown to be a marker for developing lung injury (<xref rid="R28" ref-type="bibr">28</xref>) and mortality in ARDS (<xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R30" ref-type="bibr">30</xref>) and has been used as the primary outcome in clinical trials in ARDS (<xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R32" ref-type="bibr">32</xref>) as well as post thoracotomy (<xref rid="R33" ref-type="bibr">33</xref>).</p>
              </sec>
              <sec>
                <title>Secondary Outcomes</title>
                <p>Prespecified trial secondary outcomes were Pa<sc>o</sc><sub>2</sub>:F<sc>io</sc><sub>2</sub> ratio, development of lung injury in the first 28 days as defined by the Berlin Criteria, ventilator and organ failure free days, 28 and 90 day survival and safety (e.g., hypercalcemia), and tolerability of cholecalciferol supplementation. Plasma VD status (25(OH)D, 1,25(OH)<sub>2</sub>D, and vitamin D binding protein DBP) predrug dose, preoperatively, postoperatively, and day 3 as well as EVLWI day 1 postoperatively (measured at 9 <sc>am</sc> on day 1). PiCCO<sub>2</sub> derived pulmonary vascular permeability index (PVPI) was added as an outcome measure prior to the conduct of the study as recent data suggest it was a better measure of alveolar-capillary permeability to differentiate nonhydrostatic edema than EVLWI (<xref rid="R34" ref-type="bibr">34</xref>).</p>
              </sec>
              <sec>
                <title>Exploratory Outcomes</title>
                <p>Details are available in the online supplemental material (Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>).</p>
              </sec>
              <sec>
                <title>Lung Water Measurements</title>
                <p>EVLWI and PVPI were measured by thermodilution (PiCCO<sub>2</sub>) as previously described (<xref rid="R35" ref-type="bibr">35</xref>, <xref rid="R36" ref-type="bibr">36</xref>). Specified time points for measurement were immediately preoperatively, within 1 hour postoperatively and day 1 postoperatively (8–9 <sc>am</sc>). Detailed methods are provided in the online supplemental material (Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>) and published trial protocol (<xref rid="R27" ref-type="bibr">27</xref>).</p>
              </sec>
              <sec>
                <title>Perioperative Care</title>
                <p>Patients underwent a two-stage transthoracic esophagectomy which included a laparoscopic abdominal stage followed by an open thoracotomy or minimally invasive technique with thoracoscopy. All approaches required OLV. Anesthesia was performed dependent on the anesthetists preferred practice. Teams were briefed to adopt a lower tidal volume and fluid-conservative hemodynamic management approach.</p>
              </sec>
              <sec>
                <title>Sample Size</title>
                <p>The trial was powered to detect a change of 20% in EVLWI with a power of 80% requiring 34 patients (68 in total) in each arm to reach the primary endpoint (two-tailed <italic>p</italic> = 0.05). An additional six patients were added to allow for dropouts, such as open/close cases, unexpected deaths, and other difficulties with data collection. Detailed information about the sample size estimate is provided in the trial protocol (<xref rid="R27" ref-type="bibr">27</xref>).</p>
              </sec>
              <sec>
                <title>Statistical Analysis</title>
                <p>Data were analyzed using Graphpad PRISM 6 software package (Graphpad, San Diego, CA). All analysis was based on Intention to treat. Continuous data were assessed for normality using the Shapiro-Wilks test and the appropriate parametric or nonparametric test applied. Statistical significance was predefined as two-tailed <italic>p</italic> value of less than 0.05. To assess the significance of differences between two sets of continuous data the unpaired <italic>t</italic> test was used for parametric data, whereas the Mann-Whitney <italic>U</italic> test was used for nonparametric data, except paired data which were assessed using paired <italic>t</italic> test (parametric) or Wilcoxon signed rank test (nonparametric). Categorical data were assessed using Fisher exact test and chi-square test for larger samples.</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <sec sec-type="subjects">
                <title>Enrollment and Patient Characteristics</title>
                <p>A total of 79 patients were enrolled in the study (Consolidated Standard of Reporting Trials) (<bold>Fig. <xref ref-type="fig" rid="F1">1</xref></bold>). Eleven patients (14%) did not receive OLV, or it was not possible to measure the primary endpoint (EVLWI at the end of surgery). Thirty-five patients in the placebo arm and 33 in the cholecalciferol arm (<italic>n</italic> = 68; 86%) went on to complete esophagectomy and primary outcome measurement. All patients (<italic>n</italic> = 76; 96%) that proceeded to surgery were included in the analysis of efficacy and safety of cholecalciferol supplementation.</p>
                <fig id="F1" position="float">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Patient Consolidated Standard of Reporting Trials flow diagram. IU = international unit, PiCCO = Pulse Contour Continuous Cardiac Output.</p>
                  </caption>
                  <graphic xlink:href="ccm-46-e1128-g001"/>
                </fig>
                <p>Patient baseline characteristics were well matched (<bold>Table <xref rid="T1" ref-type="table">1</xref></bold>). All procedures were performed for malignancy, and the predominant cell type was adenocarcinoma. Groups were well matched with respect to operative and anesthetic interventions (<bold>Table <xref rid="T2" ref-type="table">2</xref></bold>).</p>
                <table-wrap id="T1" position="float">
                  <label>TABLE 1.</label>
                  <caption>
                    <p>Patient Baseline Characteristics</p>
                  </caption>
                  <graphic xlink:href="ccm-46-e1128-g002"/>
                </table-wrap>
                <table-wrap id="T2" position="float">
                  <label>TABLE 2.</label>
                  <caption>
                    <p>Anesthetic and Operative Characteristics</p>
                  </caption>
                  <graphic xlink:href="ccm-46-e1128-g003"/>
                </table-wrap>
              </sec>
              <sec>
                <title>Primary Outcome</title>
                <p>There was no difference in the a priori primary outcome of change in EVLWI measured within 1 hour postoperatively placebo median +1.0 (interquartile range [IQR], 0.4–1.8) versus cholecalciferol median +0.4 mL/kg (IQR, –0.4 to –1.2 mL/kg); <italic>p</italic> value equals to 0.059 (<bold>Fig. <xref ref-type="fig" rid="F2">2</xref><italic>A</italic></bold>). There was no difference in absolute EVLWI between placebo and cholecalciferol arms postoperatively or postoperative day 1 time points (<bold>Table E1</bold>, Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>). In a within-group analysis, EVLWI rose significantly preoperatively to postoperatively only in the placebo group (<bold>Fig. E1</bold>, Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>).</p>
                <fig id="F2" position="float">
                  <label>Figure 2.</label>
                  <caption>
                    <p><bold>A</bold>, Scatter plot of fold change in extravascular lung water index (EVLWI). <bold>B</bold>, Scatter plot of fold change in pulmonary vascular permeability index (PVPI). Fold changes shown from pre- to postoperative and preoperative to day 1; <italic>black lines</italic> and <italic>squares dots</italic> placebo (<italic>n</italic> = 35); <italic>gray lines</italic> and <italic>triangle dots</italic> cholecalciferol treatment (<italic>n</italic> = 33); and data presented as medians and interquartile ranges. <italic>p</italic> values represent Mann-Whitney <italic>U</italic> test.</p>
                  </caption>
                  <graphic xlink:href="ccm-46-e1128-g004"/>
                </fig>
              </sec>
              <sec>
                <title>Secondary Outcomes</title>
                <p><bold><italic>Effects on Perioperative Changes in PVPI.</italic></bold> The change in PVPI in placebo patients was median 0.4 (IQR, 0–0.7) versus cholecalciferol median 0.1 (IQR, –0.15 to –0.35); <italic>p</italic> value equals to 0.027 (<bold>Fig. <xref ref-type="fig" rid="F2">2</xref><italic>B</italic></bold>). There was no difference seen in absolute values of PVPI preoperatively, postoperatively, and at day 1 between the groups (<bold>Table E2</bold>, Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>). In a within-group analysis PVPI significantly increased pre- to postoperatively in patients who received placebo, but not VD (<bold>Fig. E2</bold>, Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>).</p>
                <p><bold><italic>Safety of Cholecalciferol Supplementation.</italic></bold> Trial medication was well tolerated with no episodes of hypercalcemia and no reported serious adverse events related to the trial medication (detailed in the online supplemental material and <bold>Table E3</bold>, Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>).</p>
                <p><bold><italic>Efficacy of Cholecalciferol Supplementation Upon VD Status Perioperatively.</italic></bold> There was no difference between groups in baseline 25(OH)D, 1,25(OH)<sub>2</sub>D, or DBP levels (Table <xref rid="T1" ref-type="table">1</xref>). A single bolus dose of 300,000 IU of cholecalciferol resulted in significant increases in plasma 25(OH)D concentration (<bold>Table <xref rid="T3" ref-type="table">3</xref></bold>).</p>
                <table-wrap id="T3" position="float">
                  <label>TABLE 3.</label>
                  <caption>
                    <p>Perioperative Change in Vitamin D Status</p>
                  </caption>
                  <graphic xlink:href="ccm-46-e1128-g005"/>
                </table-wrap>
                <p>On the day of operation 58% of patients who received placebo were deficient (25(OH)D concentrations &lt; 50 nmol/L) compared with 5% of patients who had received the cholecalciferol single bolus dose (χ<sup>2</sup> [1, <italic>n</italic> = 76] =22.36; <italic>p</italic> &lt; 0.0001).</p>
                <p>1,25(OH)<sub>2</sub>D concentrations increased significantly in patients randomized to receive cholecalciferol (Table <xref rid="T3" ref-type="table">3</xref>) although this did not result in significantly different 1,25(OH)<sub>2</sub>D levels between groups. There was no significant change in plasma DBP concentrations.</p>
                <p>Following the surgical insult concentrations of 25(OH)D and DBP decreased in both groups, but there were persistently higher 25(OH)D concentrations in the cholecalciferol treated arm day 3 postoperatively (Table <xref rid="T3" ref-type="table">3</xref>). This meant that in the placebo group VDD was present in 58% on the day of operation and 90% by day 3. For the cholecalciferol supplemented patients, 5% were deficient at the time of operation increasing to 49% by day 3 postoperatively, demonstrating that critical illness induces VDD in this patient group for the first time.</p>
                <p><bold><italic>Clinical Outcomes.</italic></bold> There was no significant difference seen in Pa<sc>o</sc><sub>2</sub>:F<sc>io</sc><sub>2</sub> ratio between the groups. There was no difference in ARDS rates between placebo and cholecalciferol treatment arms (placebo 4 [11%] of 35 compared with cholecalciferol 4 [12%] of 33; odds ratio, 0.94; 95% CI, 0.21–4.09). There was no difference seen in ventilator-free and organ failure free days or survival (28 or 90 d) (detailed in the online supplemental material, Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>; and <bold>Table E4</bold>, Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>). No patients developed renal or cardiac failure in the first 7 days.</p>
                <p><bold><italic>Exploratory Outcomes.</italic></bold> Details can be viewed in <bold>Table E5</bold> (Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>).</p>
                <p><bold><italic>Exploratory Post Hoc Analysis of EVLWI and PVPI Measurements.</italic></bold> Only 58 % of placebo-treated and 5% of cholecalciferol treated patients were VDD on the day of the operation. Therefore a post hoc exploratory-pooled analysis of all patients irrespective of treatment arm was performed to determine if there is a threshold effect above which the beneficial effects of 25(OH)D on EVLWI and PVPI are seen. VD sufficient patients (&gt; 50 nmol/L) on the day of operation had significantly lower increases in EVLWI and PVPI compared with those who were deficient irrespective of treatment allocation (<bold>Fig. E3</bold>, Supplemental Digital Content 1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/CCM/D967">http://links.lww.com/CCM/D967</ext-link>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>In this phase 2 biological efficacy study, we sought to determine if high-dose cholecalciferol replacement attenuates the increase in alveolar-capillary permeability and development of pulmonary edema after esophagectomy. The main finding was that 300,000 IU of oral cholecalciferol treatment pre-esophagectomy did not reduce the change in EVLWI postoperatively but did reduce the change in PVPI.</p>
              <p>Vitamin D3, or cholecalciferol, is mainly formed in the skin after exposure to sunlight (ultraviolet B). Synthesized or dietary VD is hydroxylated in the liver by CYP27A1, CYP2R1, and CYP3A4 to 25-hydroxyvitamin D<sub>3</sub> [25(OH)D] the major circulating form of VD which is widely accepted as the key measure of VD status (<xref rid="R37" ref-type="bibr">37</xref>). In humans, 25(OH)D is bound to its binding protein (DBP) and requires hydroxylation to the active 1,25-dihydroxyvitamin D<sub>3</sub> [1,25(OH)<sub>2</sub>D] by the mitochondrial enzyme CYP27B1 (<xref rid="R37" ref-type="bibr">37</xref>) in order to activate the VD receptor (VDR) which mediates the biological actions of 1,25(OH)<sub>2</sub>D. Both CYP27B1 and VDR are expressed by cells of the innate and adaptive immune system as well as alveolar epithelial cells (<xref rid="R38" ref-type="bibr">38</xref>, <xref rid="R39" ref-type="bibr">39</xref>).</p>
              <p>Our hypothesis was based upon experimental data: alveolar epithelial cells possess the ability to convert circulating 25(OH)D to active 1,25(OH)<sub>2</sub>D and activate VDR responsive genes (<xref rid="R39" ref-type="bibr">39</xref>), suggesting organ-specific effects. Physiologically relevant doses of 25(OH)D stimulate wound repair, cellular proliferation, and reduce soluble Fas ligand induced cell death of human type 2 alveolar epithelial cells in vitro (<xref rid="R25" ref-type="bibr">25</xref>), suggesting that cholecalciferol has a direct protective role on the alveolar epithelium. There may also be a protective mechanism on the pulmonary endothelium as 1,25(OH)<sub>2</sub>D has been shown to decrease expression of intercellular adhesion molecule-1 and prevent neutrophil adhesion, migration and therefore potentially the initiation of lung injury (<xref rid="R40" ref-type="bibr">40</xref>). Furthermore, observational studies have found that VDD is common in patients with sepsis and ARDS and an increased risk of developing ARDS in patients undergoing esophagectomy (<xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R25" ref-type="bibr">25</xref>).</p>
              <p>The changes in PVPI and EVLWI, we observed in this study were smaller than the observational studies led us to expect. This may reflect a change in baseline VD status in the population studied, which were not as deficient as the patient cohort that this study was powered on—median 25(OH)D 25.5 nmol/L (<xref rid="R25" ref-type="bibr">25</xref>) compared with 43.2 nmol/L in the current study, suggesting that the beneficial effects of replacement may be greater in those with more severe VDD. Additionally, improved surgical technique and anesthetic management may also explain the smaller postoperative increases in EVLWI and PVPI between the two studies that were 5 years apart.</p>
              <p>High-dose cholecalciferol successfully increased 25(OH)D concentrations above sufficiency (50 nmol/L) in 94.7% of cases leading to a corresponding and sustained rise in 1,25(OH)<sub>2</sub>D level perioperatively. However, following surgical trauma induced by esophagectomy, both arms had significant falls in 25(OH)D day 3 postoperatively demonstrating that critical illness can rapidly induce a state of 25(OH)D deficiency. The placebo group also saw similar falls in circulating 1,25(OH)<sub>2</sub>D perioperatively but not in the patients who received cholecalciferol, indicating that patients in the placebo group have insufficient circulating 25(OH)D to maintain plasma concentrations of 1,25(OH)<sub>2</sub>D in the perioperative period.</p>
              <p>It is unclear how critical illness promotes this rapid fall, but our data suggest that perioperative falls in circulating DBP, the major carrier protein produced by the liver may be important. Although this could be accounted for by hemodilution (<xref rid="R41" ref-type="bibr">41</xref>), the cause of loss of binding proteins in acute inflammation is still unknown and could also be related to interstitial extravasation from increased vascular permeability following inflammatory responses and decreased hepatic synthesis (<xref rid="R42" ref-type="bibr">42</xref>). In addition, enhanced induction of activation to 1,25(OH)<sub>2</sub>D or catabolic pathways such as the formation of 24-hydroxylated or three epimer forms of VD that have recently been identified may also play a role (<xref rid="R43" ref-type="bibr">43</xref>).</p>
              <p>There is also evidence that VD may be a negative acute-phase reactant postelective knee arthroscopy (<xref rid="R44" ref-type="bibr">44</xref>) and in acute pancreatitis in which it recovers without supplementation (<xref rid="R45" ref-type="bibr">45</xref>). We believe this is an important area for future research as it is critical to inform dosing regimens for further studies into rapid VD replacement in critically ill patients. Patients may require repeat dosing rather than the large single doses so far investigated and serum 25(OH)D may be an unreliable marker of VD status after an acute inflammatory insult (<xref rid="R46" ref-type="bibr">46</xref>).</p>
              <p>Importantly high-dose cholecalciferol therapy was well tolerated with no frequency of hypercalcemia. The frequency of ARDS in this cohort was 11.7%. Cholecalciferol treatment did not prevent the development of ARDS, and there was no difference in other clinical outcomes, although our study was not powered to detect differences in clinical outcomes.</p>
              <p>This study has limitations. The changes observed in PVPI and EVLWI were much lower than previously observed possibly due to the current cohort being very much less VD deficient than previously with significant numbers of patients in the control arm not being VD deficient. The lower than expected PiCCO changes and low frequency of ARDS may have led to a type II error with no difference seen in the primary outcome. The timing of the dose was not uniform, but this did not impact the level of sufficiency in the VD group on the day of operation. Our primary outcome was a measure of potential in vivo efficacy of VD on the lung barrier, but measurements of PiCCO EVLWI have limitations of under- and over-estimation due to positive end-expiratory pressure, changes in pulmonary vascular occlusion, heterogeneous lung injury, and operator-dependency (<xref rid="R30" ref-type="bibr">30</xref>). Finally, recent studies suggest that higher doses than we used and alternative routes of administration may be more efficacious in critical illness (<xref rid="R47" ref-type="bibr">47</xref>) and sepsis (<xref rid="R48" ref-type="bibr">48</xref>), but none have investigated effects on lung injury. Our results also support the hypothesis of benefit in the more deficient cohort and the use of a follow-up maintenance dose which we did not use. Clearly, the optimum dose of VD, best route of administration, complex metabolic pathways, and multiple isoforms that influence its bioactivity need to be established in sepsis, ARDS, and critical illness before large-scale trials are undertaken.</p>
            </sec>
            <sec sec-type="conclusions">
              <title>CONCLUSIONS</title>
              <p>A single preoperative dose of cholecalciferol did not reduce EVLWI in the human esophagectomy model of lung injury. There was some effect on PVPI. Surgical insult results in a precipitous decrease in VD concentrations, which is an important consideration for future trial design to address clinical efficacy of VD therapy in ARDS and critical illness. It is clear that the ability to rapidly identify critically ill patients who are deficient in VD is a necessary precursor to trial enrollment of VD replacement in critically ill patients.</p>
            </sec>
            <sec>
              <title>ACKNOWLEDGMENTS</title>
              <p>We thank all the research, preoperative nursing, anesthetic, and surgical teams at University Hospitals Birmingham NHS Foundation Trust, Heart of England NHS Foundation Trust, and University Hospital Coventry and Warwickshire NHS Trust. In particular, Dr. Simon Smart, Dr. Jeremy Marwick, Mr. John Whiting, Mr. Ewen Griffiths, and Professor Derek Alderson from the University Hospitals Birmingham NHS Foundation Trust; Mr. Raj Nijjar, Mr. Martin Richardson; and Dr. Ruth McKenzie from the Heart of England NHS Foundation Trust. We are extremely grateful to Dr. Keith Couper and Teresa Melody from the Academic Department of Anesthesia, Critical Care, Resuscitation and Pain Department, Heart of England NHS Foundation Trust for helping to facilitate patient recruitment and trial delivery, and Dr. Anita Pye for providing overall trial support and coordination. We are grateful to Mr. Rajnikant Mehta for his independent senior statistical review of the data analysis and interpretation.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <fig id="s1" position="anchor">
                <media xlink:href="ccm-46-e1128-s001.docx"/>
              </fig>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p>
                  <bold>*See also p. 2064.</bold>
                </p>
              </fn>
              <fn fn-type="other">
                <p>Drs. Parekh and Dancer are joint first authors.</p>
              </fn>
              <fn fn-type="other">
                <p>Clinical trial registered with the International Standard Randomized Controlled Trial Registry (ISRCTN27673620) and European Union database of Randomized Controlled Trials (EudraCT 2012-000332-25).</p>
              </fn>
              <fn fn-type="equal">
                <p>Drs. Parekh, Fraser, Gao, Martineau, Perkins, and Thickett designed the study. Drs. Cooper, Tan, and Tucker provided expert advice and aided recruitment. Drs. Parekh, Dancer, Howells, and Mahida recruited patients. Drs. Parekh, Dancer, Scott, D’Souza, and Tang undertook biomarker assays and analyzed the data. Drs. Parekh, Dancer, and Thickett wrote the first draft of the article. All authors contributed to revising the draft critically for important intellectual content and have agreed to the final submitted version.</p>
              </fn>
              <fn fn-type="other">
                <p>Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (<ext-link ext-link-type="uri" xlink:href="http://journals.lww.com/ccmjournal">http://journals.lww.com/ccmjournal</ext-link>).</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p>Dr. Parekh was funded by the Medical Research Council (MRC) (MR/J011266/1); Drs. Dancer and Thickett by the MRC (G1100196/1) trust; and Dr. Scott by the MRC (MR/L002736/1). Drs. Gao and Perkins are National Institute for Health Research Senior Investigators. Drs. Parekh, Dancer, Mahida, Tang, and Thickett received support for article research from Research Councils UK. Drs. Dancer, Tang, and Thickett’s institutions received funding from the MRC. Dr. Howells institution received funding from GlaxoSmithKline. Dr. Perkins disclosed off-label product use of vitamin D. The remaining authors have disclosed that they do not have any potential conflicts of interest.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="R1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gajic</surname><given-names>O</given-names></name><name><surname>Dabbagh</surname><given-names>O</given-names></name><name><surname>Park</surname><given-names>PK</given-names></name><etal/></person-group>; <collab>U.S. Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITG-LIPS)</collab>: <article-title>Early identification of patients at risk of acute lung injury: Evaluation of lung injury prediction score in a multicenter cohort study.</article-title><source>Am J Respir Crit Care Med</source><year>2011</year>; <volume>183</volume>:<fpage>462</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">20802164</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkins</surname><given-names>GD</given-names></name><name><surname>Gates</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>D</given-names></name><etal/></person-group>; <collab>BALTI-Prevention Collaborators</collab>: <article-title>The beta agonist lung injury trial prevention. A randomized controlled trial.</article-title><source>Am J Respir Crit Care Med</source><year>2014</year>; <volume>189</volume>:<fpage>674</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">24392848</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kor</surname><given-names>DJ</given-names></name><name><surname>Carter</surname><given-names>RE</given-names></name><name><surname>Park</surname><given-names>PK</given-names></name><etal/></person-group>; <collab>US Critical Illness and Injury Trials Group: Lung Injury Prevention with Aspirin Study Group (USCIITG: LIPS-A)</collab>: <article-title>Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: The LIPS-a randomized clinical trial.</article-title><source>JAMA</source><year>2016</year>; <volume>315</volume>:<fpage>2406</fpage><lpage>2414</lpage><pub-id pub-id-type="pmid">27179988</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beitler</surname><given-names>JR</given-names></name><name><surname>Schoenfeld</surname><given-names>DA</given-names></name><name><surname>Thompson</surname><given-names>BT</given-names></name></person-group><article-title>Preventing ARDS: Progress, promise, and pitfalls.</article-title><source>Chest</source><year>2014</year>; <volume>146</volume>:<fpage>1102</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">25288000</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>DJ</given-names></name><name><surname>Jamieson</surname><given-names>GG</given-names></name><name><surname>Watson</surname><given-names>DI</given-names></name><etal/></person-group><article-title>Perioperative risk analysis for acute respiratory distress syndrome after elective oesophagectomy.</article-title><source>ANZ J Surg</source><year>2011</year>; <volume>81</volume>:<fpage>700</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">22295310</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tandon</surname><given-names>S</given-names></name><name><surname>Batchelor</surname><given-names>A</given-names></name><name><surname>Bullock</surname><given-names>R</given-names></name><etal/></person-group><article-title>Peri-operative risk factors for acute lung injury after elective oesophagectomy.</article-title><source>Br J Anaesth</source><year>2001</year>; <volume>86</volume>:<fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">11575337</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>DP</given-names></name><name><surname>Welch</surname><given-names>CA</given-names></name><name><surname>Harrison</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Outcomes following oesophagectomy in patients with oesophageal cancer: A secondary analysis of the ICNARC Case Mix Programme Database.</article-title><source>Crit Care</source><year>2009</year>; <volume>13</volume>(<issue>Suppl 2</issue>):<fpage>S1</fpage></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagano</surname><given-names>A</given-names></name><name><surname>Barazzone-Argiroffo</surname><given-names>C</given-names></name></person-group><article-title>Alveolar cell death in hyperoxia-induced lung injury.</article-title><source>Ann N Y Acad Sci</source><year>2003</year>; <volume>1010</volume>:<fpage>405</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">15033761</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carnesecchi</surname><given-names>S</given-names></name><name><surname>Deffert</surname><given-names>C</given-names></name><name><surname>Pagano</surname><given-names>A</given-names></name><etal/></person-group><article-title>NADPH oxidase-1 plays a crucial role in hyperoxia-induced acute lung injury in mice.</article-title><source>Am J Respir Crit Care Med</source><year>2009</year>; <volume>180</volume>:<fpage>972</fpage><lpage>981</lpage><pub-id pub-id-type="pmid">19661248</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>RS</given-names></name><name><surname>Andrade</surname><given-names>CF</given-names></name></person-group><article-title>Oxidative stress and lung ischemia-reperfusion injury.</article-title><source>Oxid Med Cell Longev</source><year>2015</year>; <volume>2015</volume>:<fpage>590987</fpage><pub-id pub-id-type="pmid">26161240</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudouin</surname><given-names>SV</given-names></name></person-group><article-title>Lung injury after thoracotomy.</article-title><source>Br J Anaesth</source><year>2003</year>; <volume>91</volume>:<fpage>132</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">12821572</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocker</surname><given-names>GM</given-names></name><name><surname>Wiseman</surname><given-names>MS</given-names></name><name><surname>Pearson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Neutrophil degranulation and increased pulmonary capillary permeability following oesophagectomy: A model of early lung injury in man.</article-title><source>Br J Surg</source><year>1988</year>; <volume>75</volume>:<fpage>883</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">3179665</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Koeda</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cytokine profile of serum and bronchoalveolar lavage fluids following thoracic esophageal cancer surgery.</article-title><source>Eur Surg Res</source><year>2001</year>; <volume>33</volume>:<fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">11684834</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Schoor</surname><given-names>NM</given-names></name><name><surname>Lips</surname><given-names>P</given-names></name></person-group><article-title>Worldwide vitamin D status.</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2011</year>; <volume>25</volume>:<fpage>671</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">21872807</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parekh</surname><given-names>D</given-names></name><name><surname>Thickett</surname><given-names>DR</given-names></name><name><surname>Turner</surname><given-names>AM</given-names></name></person-group><article-title>Vitamin D deficiency and acute lung injury.</article-title><source>Inflamm Allergy Drug Targets</source><year>2013</year>; <volume>12</volume>:<fpage>253</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">23782208</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Eisman</surname><given-names>JA</given-names></name><name><surname>Center</surname><given-names>JR</given-names></name></person-group><article-title>Vitamin D deficiency in critically ill patients.</article-title><source>N Engl J Med</source><year>2009</year>; <volume>360</volume>:<fpage>1912</fpage><lpage>1914</lpage><pub-id pub-id-type="pmid">19403914</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quraishi</surname><given-names>SA</given-names></name><name><surname>Litonjua</surname><given-names>AA</given-names></name><name><surname>Moromizato</surname><given-names>T</given-names></name><etal/></person-group><article-title>Association between prehospital vitamin D status and hospital-acquired bloodstream infections.</article-title><source>Am J Clin Nutr</source><year>2013</year>; <volume>98</volume>:<fpage>952</fpage><lpage>959</lpage><pub-id pub-id-type="pmid">23945717</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moromizato</surname><given-names>T</given-names></name><name><surname>Litonjua</surname><given-names>AA</given-names></name><name><surname>Braun</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Association of low serum 25-hydroxyvitamin D levels and sepsis in the critically ill.</article-title><source>Crit Care Med</source><year>2014</year>; <volume>42</volume>:<fpage>97</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">23982028</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thickett</surname><given-names>DR</given-names></name><name><surname>Moromizato</surname><given-names>T</given-names></name><name><surname>Litonjua</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Association between prehospital vitamin D status and incident acute respiratory failure in critically ill patients: A retrospective cohort study.</article-title><source>BMJ Open Respir Res</source><year>2015</year>; <volume>2</volume>:<fpage>e000074</fpage></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>AB</given-names></name><name><surname>Litonjua</surname><given-names>AA</given-names></name><name><surname>Moromizato</surname><given-names>T</given-names></name><etal/></person-group><article-title>Association of low serum 25-hydroxyvitamin D levels and acute kidney injury in the critically ill.</article-title><source>Crit Care Med</source><year>2012</year>; <volume>40</volume>:<fpage>3170</fpage><lpage>3179</lpage><pub-id pub-id-type="pmid">22975885</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parekh</surname><given-names>D</given-names></name><name><surname>Patel</surname><given-names>JM</given-names></name><name><surname>Scott</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vitamin D deficiency in human and murine sepsis.</article-title><source>Crit Care Med</source><year>2017</year>; <volume>45</volume>:<fpage>282</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">27632669</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>AB</given-names></name><name><surname>Gibbons</surname><given-names>FK</given-names></name><name><surname>Litonjua</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Low serum 25-hydroxyvitamin D at critical care initiation is associated with increased mortality*.</article-title><source>Crit Care Med</source><year>2012</year>; <volume>40</volume>:<fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">21926604</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cecchi</surname><given-names>A</given-names></name><name><surname>Bonizzoli</surname><given-names>M</given-names></name><name><surname>Douar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Vitamin D deficiency in septic patients at ICU admission is not a mortality predictor.</article-title><source>Minerva Anestesiol</source><year>2011</year>; <volume>77</volume>:<fpage>1184</fpage><lpage>1189</lpage><pub-id pub-id-type="pmid">21720281</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucidarme</surname><given-names>O</given-names></name><name><surname>Messai</surname><given-names>E</given-names></name><name><surname>Mazzoni</surname><given-names>T</given-names></name><etal/></person-group><article-title>Incidence and risk factors of vitamin D deficiency in critically ill patients: Results from a prospective observational study.</article-title><source>Intensive Care Med</source><year>2010</year>; <volume>36</volume>:<fpage>1609</fpage><lpage>1611</lpage><pub-id pub-id-type="pmid">20373095</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dancer</surname><given-names>RC</given-names></name><name><surname>Parekh</surname><given-names>D</given-names></name><name><surname>Lax</surname><given-names>S</given-names></name><etal/></person-group><article-title>Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS).</article-title><source>Thorax</source><year>2015</year>; <volume>70</volume>:<fpage>617</fpage><lpage>624</lpage><pub-id pub-id-type="pmid">25903964</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dancer</surname><given-names>R</given-names></name><name><surname>Parekh</surname><given-names>D</given-names></name><name><surname>Scott</surname><given-names>A</given-names></name><etal/></person-group><article-title>T2 Vitamin D supplementation reduces perioperative systemic and alveolar inflammation in patients undergoing oesophagectomy: Results of the Vindaloo Trial.</article-title><source>Thorax</source><year>2015</year>; <volume>70</volume>(<issue>Suppl 3</issue>):<fpage>A1</fpage></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parekh</surname><given-names>D</given-names></name><name><surname>Dancer</surname><given-names>RC</given-names></name><name><surname>Lax</surname><given-names>S</given-names></name><etal/></person-group><article-title>Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): Study protocol for a randomised placebo controlled trial.</article-title><source>Trials</source><year>2013</year>; <volume>14</volume>:<fpage>100</fpage><pub-id pub-id-type="pmid">23782429</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kor</surname><given-names>DJ</given-names></name><name><surname>Warner</surname><given-names>DO</given-names></name><name><surname>Carter</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Extravascular lung water and pulmonary vascular permeability index as markers predictive of postoperative acute respiratory distress syndrome: A prospective cohort investigation.</article-title><source>Crit Care Med</source><year>2015</year>; <volume>43</volume>:<fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">25513786</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jozwiak</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>S</given-names></name><name><surname>Persichini</surname><given-names>R</given-names></name><etal/></person-group><article-title>Extravascular lung water is an independent prognostic factor in patients with acute respiratory distress syndrome*.</article-title><source>Crit Care Med</source><year>2013</year>; <volume>41</volume>:<fpage>472</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">23263578</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jozwiak</surname><given-names>M</given-names></name><name><surname>Teboul</surname><given-names>JL</given-names></name><name><surname>Monnet</surname><given-names>X</given-names></name></person-group><article-title>Extravascular lung water in critical care: Recent advances and clinical applications.</article-title><source>Ann Intensive Care</source><year>2015</year>; <volume>5</volume>:<fpage>38</fpage><pub-id pub-id-type="pmid">26546321</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkins</surname><given-names>GD</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Thickett</surname><given-names>DR</given-names></name><etal/></person-group><article-title>The beta-agonist lung injury trial (BALTI): A randomized placebo-controlled clinical trial.</article-title><source>Am J Respir Crit Care Med</source><year>2006</year>; <volume>173</volume>:<fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">16254268</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>TR</given-names></name><name><surname>Duffy</surname><given-names>MJ</given-names></name><name><surname>Shyamsundar</surname><given-names>M</given-names></name><etal/></person-group><article-title>A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study).</article-title><source>Am J Respir Crit Care Med</source><year>2011</year>; <volume>183</volume>:<fpage>620</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">20870757</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Licker</surname><given-names>M</given-names></name><name><surname>Tschopp</surname><given-names>JM</given-names></name><name><surname>Robert</surname><given-names>J</given-names></name><etal/></person-group><article-title>Aerosolized salbutamol accelerates the resolution of pulmonary edema after lung resection.</article-title><source>Chest</source><year>2008</year>; <volume>133</volume>:<fpage>845</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">17989152</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kushimoto</surname><given-names>S</given-names></name><name><surname>Taira</surname><given-names>Y</given-names></name><name><surname>Kitazawa</surname><given-names>Y</given-names></name><etal/></person-group>; <collab>PiCCO Pulmonary Edema Study Group</collab>: <article-title>The clinical usefulness of extravascular lung water and pulmonary vascular permeability index to diagnose and characterize pulmonary edema: A prospective multicenter study on the quantitative differential diagnostic definition for acute lung injury/acute respiratory distress syndrome.</article-title><source>Crit Care</source><year>2012</year>; <volume>16</volume>:<fpage>R232</fpage><pub-id pub-id-type="pmid">23232188</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkins</surname><given-names>GD</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Thickett</surname><given-names>DR</given-names></name></person-group><article-title>In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury.</article-title><source>Thorax</source><year>2008</year>; <volume>63</volume>:<fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">17951278</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>TR</given-names></name><name><surname>Duffy</surname><given-names>MJ</given-names></name><name><surname>Shyamsundar</surname><given-names>M</given-names></name><etal/></person-group><article-title>Extravascular lung water indexed to predicted body weight is a novel predictor of intensive care unit mortality in patients with acute lung injury.</article-title><source>Crit Care Med</source><year>2010</year>; <volume>38</volume>:<fpage>114</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">19789451</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holick</surname><given-names>MF</given-names></name></person-group><article-title>Vitamin D deficiency.</article-title><source>N Engl J Med</source><year>2007</year>; <volume>357</volume>:<fpage>266</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">17634462</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>JS</given-names></name><name><surname>Hewison</surname><given-names>M</given-names></name></person-group><article-title>Unexpected actions of vitamin D: New perspectives on the regulation of innate and adaptive immunity.</article-title><source>Nat Clin Pract Endocrinol Metab</source><year>2008</year>; <volume>4</volume>:<fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">18212810</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansdottir</surname><given-names>S</given-names></name><name><surname>Monick</surname><given-names>MM</given-names></name><name><surname>Hinde</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Respiratory epithelial cells convert inactive vitamin D to its active form: Potential effects on host defense.</article-title><source>J Immunol</source><year>2008</year>; <volume>181</volume>:<fpage>7090</fpage><lpage>7099</lpage><pub-id pub-id-type="pmid">18981129</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SF</given-names></name></person-group><article-title>1 alpha, 25-dihydroxyvitamin D3 decreased ICAM-1 and ELAM-1 expressions on pulmonary microvascular endothelial cells and neutrophil motivation.</article-title><source>J Steroid Biochem Mol Biol</source><year>1995</year>; <volume>52</volume>:<fpage>67</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">7532002</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>A</given-names></name><name><surname>Ochola</surname><given-names>J</given-names></name><name><surname>Mundy</surname><given-names>J</given-names></name><etal/></person-group><article-title>Acute fluid shifts influence the assessment of serum vitamin D status in critically ill patients.</article-title><source>Crit Care</source><year>2010</year>; <volume>14</volume>:<fpage>R216</fpage><pub-id pub-id-type="pmid">21110839</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quraishi</surname><given-names>SA</given-names></name><name><surname>Camargo</surname><given-names>CA</given-names><suffix>Jr</suffix></name></person-group><article-title>Vitamin D in acute stress and critical illness.</article-title><source>Curr Opin Clin Nutr Metab Care</source><year>2012</year>; <volume>15</volume>:<fpage>625</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">23075939</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkinson</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>AE</given-names></name><name><surname>Hassan-Smith</surname><given-names>ZK</given-names></name><etal/></person-group><article-title>High throughput LC-MS/MS method for the simultaneous analysis of multiple vitamin D analytes in serum.</article-title><source>J Chromatogr B Analyt Technol Biomed Life Sci</source><year>2016</year>; <volume>1014</volume>:<fpage>56</fpage><lpage>63</lpage></mixed-citation>
              </ref>
              <ref id="R44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>D</given-names></name><name><surname>Toole</surname><given-names>BJ</given-names></name><name><surname>Knox</surname><given-names>S</given-names></name><etal/></person-group><article-title>The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty.</article-title><source>Am J Clin Nutr</source><year>2011</year>; <volume>93</volume>:<fpage>1006</fpage><lpage>1011</lpage><pub-id pub-id-type="pmid">21411617</pub-id></mixed-citation>
              </ref>
              <ref id="R45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>UC</given-names></name><name><surname>Novovic</surname><given-names>S</given-names></name><name><surname>Andersen</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Variations in serum 25-hydroxyvitamin D during acute pancreatitis: An exploratory longitudinal study.</article-title><source>Endocr Res</source><year>2011</year>; <volume>36</volume>:<fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">21973232</pub-id></mixed-citation>
              </ref>
              <ref id="R46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousefzadeh</surname><given-names>P</given-names></name><name><surname>Shapses</surname><given-names>SA</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Vitamin D binding protein impact on 25-hydroxyvitamin D levels under different physiologic and pathologic conditions.</article-title><source>Int J Endocrinol</source><year>2014</year>; <volume>2014</volume>:<fpage>981581</fpage><pub-id pub-id-type="pmid">24868205</pub-id></mixed-citation>
              </ref>
              <ref id="R47">
                <label>47.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amrein</surname><given-names>K</given-names></name><name><surname>Schnedl</surname><given-names>C</given-names></name><name><surname>Holl</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: The VITdAL-ICU randomized clinical trial.</article-title><source>JAMA</source><year>2014</year>; <volume>312</volume>:<fpage>1520</fpage><lpage>1530</lpage><pub-id pub-id-type="pmid">25268295</pub-id></mixed-citation>
              </ref>
              <ref id="R48">
                <label>48.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quraishi</surname><given-names>SA</given-names></name><name><surname>De Pascale</surname><given-names>G</given-names></name><name><surname>Needleman</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Effect of cholecalciferol supplementation on vitamin D status and cathelicidin levels in sepsis: A randomized, placebo-controlled trial.</article-title><source>Crit Care Med</source><year>2015</year>; <volume>43</volume>:<fpage>1928</fpage><lpage>1937</lpage><pub-id pub-id-type="pmid">26086941</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
